Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    132
    ...
ATC Name B/G Ingredients Dosage Form Price
A10BB12 DIAMERIL G Glimepiride - 1mg 1mg Tablet 130,545 L.L
J01MA14 LOXIPHAR G Moxifloxacin (HCl) - 400mg 400mg Tablet 1,063,555 L.L
N03AX14 LEPITAM G Levetiracetam - 250mg 250mg Tablet 700,078 L.L
A03FA01 METOCLOPRAMIDE G Metoclopramide HCl - 10mg 10mg Tablet 172,012 L.L
A10BB12 GLIM G Glimepiride - 1mg 1mg Tablet 302,365 L.L
V03AE07 PHOSPHOLOW G Calcium acetate - 660mg 660mg Tablet 1,118,077 L.L
A10BB12 GLUMYL 1 G Glimepiride - 1mg 1mg Tablet 186,858 L.L
A10BB12 ORBIDE G Glimepiride - 1mg 1mg Tablet 207,336 L.L
L04AA10 RAPAMUNE B Sirolimus - 1mg 1mg Tablet 12,907,489 L.L
L01EA02 APO-DASATINIB G Dasatinib - 70mg 70mg Tablet L.L
A10BB12 AMARYL B Glimepiride - 2mg 2mg Tablet 233,829 L.L
C07AB07 BISCORDEX G Bisoprolol fumarate - 10mg 10mg Tablet 789,667 L.L
C09DA04 IRTAN PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 25mg 300mg Tablet 601,530 L.L
R06AD02 PROMETAL G Promethazine - 25mg 25mg Tablet 194,537 L.L
A10BB12 AMEPRIDE G Glimepiride - 2mg 2mg Tablet 139,760 L.L
C09DA06 ATACAND PLUS B Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 705,517 L.L
J01MA23 BAXDELA B Delafloxacin - 450mg 450mg Tablet 93,777,847 L.L
R06AD02 PROMETAL G Promethazine - 25mg 25mg Tablet 8,003,607 L.L
A10BB12 DIAMERIL G Glimepiride - 2mg 2mg Tablet 199,657 L.L
C09DA06 BLOPRESS PLUS 16MG B Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 1,040,134 L.L
N03AX14 LEPITAM G Levetiracetam - 500mg 500mg Tablet 1,100,671 L.L
A10BB12 GLIM G Glimepiride - 2mg 2mg Tablet 401,809 L.L
C09DA06 ARKANDA PLUS 16/12.5 G Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg 32mg Tablet 642,485 L.L
A10BB12 GLUMYL 2 G Glimepiride - 2mg 2mg Tablet 189,418 L.L
C09DA06 CANDESARTAN / HYDROCHLOROTHIAZIDE BIOGARAN G Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 327,898 L.L
G01AA51 TERGYNAN G Nystatin - 100000IU, Neomycin (sulfate) - 65000IU, Metronidazole - 500mg Tablet 348,055 L.L
A03FA03 MOTILIUM B Domperidone - 10mg 10mg Tablet 353,431 L.L
A10BB12 GLYPRIDE G Glimepiride - 2mg 2mg Tablet 403,153 L.L
C09DA06 BLOPRESS PLUS 8MG B Candesartan cilexetil - 8mg, Hydrochlorothiazide - 12.5mg Tablet 806,306 L.L
G01AC05 FLUOMIZIN B Dequalinium chloride - 10mg 10mg Tablet 775,397 L.L
    ...
    132
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026